Full Press Release Details
Dan Yerace Co - Founder & VP Operations 10+ years of pharmaceutical experience including roles in global supply chain, operations, business development, and procurement Colleen Delaney MD, MSc CSO & CMO World - renowned expert in cell and gene therapy research with 20+ years' experience in the translation of scientific discovery to clinical practice, including all aspects of cell therapy product development Brian Cogley Chief Financial Officer 15 + years of corporate financial experience in life sciences, pharmaceuticals, and financial services, expertise in asset management, and investments 19 2023 Coeptis Therapeutics Holdings, Inc.
Anti - CD38 mAbs (Infused antibodies from current cancer treatments) bind to CD38 proteins and kill both CD38+ Cancer cells and our body's Natural Killer Cells. CD38 - GEAR - NK are modified, NK cells that we believe can avoid being ablated by therapies designed to target the CD38 antigen, potentially enabling the combination of passive immunity with innate active immunity to more efficiently target and eradicate CD38+ malignancies.
THE GOAL To protect CD38+ Natural Killer (NK) cells so that functional disease - targeting NK cells will not be eradicated, enabling their co - existence with CD38 targeting therapies, and thus allowing for complementary tumor killing and immune surveillance. A NOVEL COMBINATORIAL APPROACH Modified NK cells that are co - administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre - clinical development to test ability to enhance and maximize tumor kill via combinatorial approaches otherwise not possible.
In that event, the trading price of our common stock could be adversely impacted, and you co uld lose part or all of your investment. Below is a summary of some of the principal risks we face: We may not be able to successfully implement our growth strategy on a timely basis or at all; We may have difficulties managing our anticipated growth, or we may not grow at all; We have a history of losses, we expect to incur losses in the future and we may not be able to achieve or maintain profitabil ity ; We may not be able to initiate and complete preclinical studies and clinical trials for our product candidates which could ad ver sely affect our business; We may not be able to obtain and maintain the third - party relationships that are necessary to develop, commercialize and manufac ture some or all of our product candidates; We may encounter difficulties in managing our growth, which could adversely affect our operations; We need to obtain financing in order to continue our operations; The drug development and approval process is uncertain, time - consuming and expensive; Competition in the biotechnology and pharmaceutical industries may result in competing products, superior marketing of other pro ducts and lower revenues or profits for us; Federal laws or regulations on drug importation could make lower cost versions of our future products available, which could adv ersely affect our revenues, if any; The regulatory approval process is costly and lengthy, and we may not be able to successfully obtain all required regulatory app rovals; Healthcare reform measures could adversely affect our business; Protecting and defending against intellectual property claims may have a material adverse effect on our business; If we are not able to retain our current senior management team and our scientific advisors or continue to attract and retain qu alified scientific, technical and business personnel, our business will suffer; and We may not be able to maintain our listing on the Nasdaq Capital Market; and There is a substantial doubt about our ability to continue as a going concern. 6 2023 Coeptis Therapeutics Holdings, Inc.
Note that there may be also additional risks that are currently n ot known about or that are currently believed to be immaterial may also impair its business, financial condition or results of operations. You sho uld review this Presentation and perform your own due diligence and consult with your own financial and legal advisors, with such risks in co nsi deration. 5 2023 Coeptis Therapeutics Holdings, Inc.
Risk Awareness. Any reader of this Presentation should be aware of the numerous risks facing Coeptis in the operation of its business and pursuit of its growth strategy. Those risks include those that are detailed in sections entitled "Risk Factors" in documents pr eviously or hereafter filed or furnished by Coeptis with the SEC, and you should carefully consider those risks and uncertainties, togeth er with the financial statements and related notes filed with the SEC.
Date of Information: This Presentation speaks only as of the date hereof. Coeptis does not intend to update or otherwise revise this Presentation following its use, except the extent required by law. Coeptis makes no representation or warranty, express or i mpl ied, as to the accuracy or completeness of any of the information contained in this Presentation. 4 2023 Coeptis Therapeutics Holdings, Inc.
To the fullest extent permitted by law, in no ci rcumstances will Coeptis or any of its subsidiaries, shareholders, affiliates, representatives, control persons, partners, members, managers, dir ectors, officers, employees, advisers or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arisi ng from the use of this Presentation, its contents, its omissions, reliance on the information contained within it, or on opinions communicated in re lat ion thereto or otherwise arising in connection therewith.
No Representation: Neither Coeptis, nor any of its subsidiaries, shareholders, affiliates, representatives, control persons, partners, members, managers, directors, officers, employees, advisers or agents make any representation or warranty, express or implied, as to t he accuracy, completeness or reliability of the information contained in this Presentation.
The forward - looking statements made in this Presentation are based on Coeptis' current assumptions and judgments regarding futur e events and results. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Ma ny actual events and circumstances are beyond the control of Coeptis. Some important factors that could cause actual results to differ ma terially from those in any forward - looking statements could include changes in domestic and foreign business, market, financial, political and legal conditions.
Forward - looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticip ate," "intend," "expect," "should," "would," "plan," "future," "outlook," and similar expressions that predict or indicate future events or t ren ds. All statements that are not statements of historical matters are forward - looking statements.
Forward - looking statements are neither historical facts nor assurances of future performance. Because forward - looking statements relate to the future, they are inherently subject to significant known and unkno wn risks, uncertainties and other factors that are difficult to predict and are beyond the control of Coeptis. The actual results, lev el of activity, performance or achievements of Coeptis may be materially different from any future results, levels of activity, performance o r a chievements expressed or implied by these forwards - looking statements.